Data / Drug companies / Complement Inhibitor
Complement Inhibitor drugs: 8 drugs from 7 companies in the FDA NDC directory
Complement Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 12 products in this class from 7 companies, covering 8 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on April 7, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 7Companies
- 12Products
- 8Drugs by generic name
Drugs in the Complement Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Zilucoplan | 3 | 1 |
| Pegcetacoplan | 2 | 1 |
| Ravulizumab | 2 | 1 |
| Avacincaptad pegol | 1 | 1 |
| Eculizumab | 1 | 1 |
| Eculizumab-aagh | 1 | 1 |
| Eculizumab-aeeb | 1 | 1 |
| Pozelimab | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alexion Pharmaceuticals Inc. | 3 | solution, concentrate; injection, solution, concentrate | Biologics (BLA) | October 9, 2020 |
| Ucb, Inc. | 3 | injection, solution | New drug applications (NDA) | January 3, 2024 |
| Apellis Pharmaceuticals, Inc. | 2 | injection, solution | New drug applications (NDA) | February 17, 2023 |
| Amgen, Inc | 1 | injection, solution, concentrate | Biologics (BLA) | March 1, 2025 |
| Astellas Pharma US, Inc. | 1 | injection | New drug applications (NDA) | August 19, 2023 |
| Regeneron Pharmaceuticals, Inc. | 1 | injection, solution | Biologics (BLA) | August 18, 2023 |
| Teva Pharmaceuticals USA, Inc. | 1 | injection, solution | Biologics (BLA) | April 7, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 7 | 58.3% |
| Solution, concentrate | 2 | 16.7% |
| Injection, solution, concentrate | 2 | 16.7% |
| Injection | 1 | 8.3% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.